Amerigroup hires chief compliance officer

Georgia Dodds Foley to lead the office of business ethics and compliance programme

US healthcare group Amerigroup Corporation has appointed Georgia Dodds Foley as chief compliance officer.

Dodds Foley joins Virginia Beach-based Amerigroup with more than two decades of experience focused on senior-level legal, compliance and ethics positions in the healthcare industry. Most recently, she was deputy compliance and ethics officer for CIGNA Corporation in Philadelphia, overseeing compliance for the organisation's domestic operations.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Regulatory

Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates

These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
Regulatory

UK-US pharma deal removes tariffs and boosts access to innovative medicines

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Regulatory

European Commission approves Teva denosumab biosimilars PONLIMSI and DEGEVMA

The two biosimilars to Prolia and Xgeva will expand access to important bone health treatments across Europe and bolster Teva's strong biosimilars portfolio
Subscribe now